Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammation and Cardiovascular Disease: Findings From a Translational Investigation
Plasma S1P (Sphingosine-1-Phosphate) Links to Hypertension and Biomarkers of Inflammation and Cardiovascular Disease: Findings From a Translational Investigation
复制标题
DOI：
10.1161/hypertensionaha.120.17379
复制
发表时间：
2021-07-01
期刊：
影响因子：
8.3
通讯作者：
Meissner, Anja
中科院分区：
文献类型：
--
作者：
Jujic, Amra;Matthes, Frank;Meissner, Anja
1-磷酸鞘氨醇（S1 P）是免疫细胞运输和血管功能障碍的重要调节剂，有助于显性高血压的发生和发展。尽管靶向S1 P信号在不同的实验性高血压研究中揭示了治疗潜力，但缺乏对人类S1 P-血压（BP）相关性的验证。在一个转化方法中，我们在一个基于家族的研究队列（MOS [马尔莫后代研究]; N=1046）和一个纵向进行的小鼠高血压队列中探索了血浆S1 P和BP之间的关联。在MOS中，线性多变量回归分析显示，血浆S1 P与收缩压升高相关（β =1.06，P=0.015）。收缩压>= 140 mm Hg的研究受试者的S1 P血浆浓度显著高于BP受试者
S1P (Sphingosine-1-phosphate) is an important regulator of immune cell trafficking and vascular dysfunction contributing to the development and progression of overt hypertension. Although targeting S1P signaling revealed therapeutic potential in different experimental hypertension studies, validations of S1P-blood pressure (BP) associations in humans are lacking. In a translational approach, we explored the associations between plasma S1P and BP in a family based study cohort (MOS [Malmo Offspring Study]; N=1046) and in a longitudinally conducted murine hypertension cohort. In MOS, linear multivariate regression analyses showed that plasma S1P associates with increased systolic BP (beta=1.06, P=0.015). Study subjects with systolic BP >= 140 mm Hg presented with significantly higher S1P plasma concentrations compared with subjects with BP